After a nice share run-up post-IPO, America's No. 1 drug app company by popularity, GoodRx Holdings (NASDAQ: GDRX), is down over 30% from its high and remains below its debut price of $46 per share. Now, many investors are wondering if they should buy the dip on some shares.
After all, who wouldn't be excited about investing in a company that genuinely helps make prescription drugs affordable for all? As it turns out, there is a key reason why GoodRx is a great business, but may not be a great investment. Can the company hold its ground against a mega-competitor that's about to enter the industry? Let's find out together.
Image source: Getty Images.
Source Fool.com